OBJECTIVE： To observe clinical efficacy and safety of Carboxymethylstarch sodium solution in auxiliary treatment of pediatric bronchial asthma. METHODS： Totally 102 children with bronchial asthma selected from our hospital during Mar. 2015-Mar. 2016 were divided into observation group and control group according to admission order， with 51 cases in each group. Control group was given aerosol inhalation of Budesonide suspension for inhalation 0.5-1 mg， tid+ aerosol inhalation of Ipratropium bromide solution for inhalation 1-2 mL+Ambroxol hydrochloride and clenbuterol hydrochloride oral solution 2.5-15 mL， po， bid. Observation group was additionally given Carboxymethylstarch sodium solution 7 mL （1-＜4 years old）， 10 mL （4-12 years old）， po， tid. Both groups received treatment for 3 months. Clinical efficacy， the time of cough and wheezing relief， the time of lung wheezing disappearance， hospitalization time and the levels of immune indexes （IgG， IgM， IgA） were observed in 2 groups， and the occurrence of ADR was recorded. RESULTS： Total response rate of observation group （90.2％） was significantly higher than that of control group （70.6％）， and the time of cough and wheezing relief， the time of lung wheezing disappearance and hospitalization time of observation group were significantly shorter than those of control group， with statistical significance （P＜0.05）. There was no statistical significance in the levels of IgG， IgM and IgA between 2 groups before treatment （P＞0.05）. After treatment， above immune indexes of observation group were significantly higher than before treatment and control group， with statistical significance （P＜0.05）. No obvious ADR was found in 2 groups during treatment. CONCLUSIONS： Carboxymethylstarch sodium solution in auxiliary treatment of pediatric bronchial asthma shows good therapeutic efficacy and improves immunity of children with good safety.